LENSAR Inc (LNSR)

LENSAR cancels Alcon merger agreement, prepares strategic updateMarch 17, 2026 11:23 AM
IH Market News
LENSAR, Inc. (NASDAQ:LNSR), a Nasdaq-listed medical technology company focused on robotic laser systems for cataract and astigmatism treatment, said on March 16, 2026 that it has mutually agreed with Alcon Research, LLC to terminate their previously announced merger agreement.The companies decided to end the deal after determining that the required U.S. regulatory approvals were unlikely to be obtained before the agreement’s outside date of April 23, 2026, or a potential extension to July 23, 2026.Under the terms of the termination, LENSAR will keep the $10 million deposit originally paid under the merger agreement. Both parties also signed a mutual release covering any claims related to the cancelled transaction.The company said the Federal Trade Commission had indicated it would seek to block the acquisition. LENSAR also acknowledged several potential risks stemming from the failed deal, including transaction-related costs, possible legal challenges, pressure on its share price and the potential difficulty of retaining employees and other stakeholders.Despite the merger’s termination, management emphasized continued momentum for the company’s ALLY Robotic Cataract Laser platform and said it plans to provide a strategic update on March 31, 2026 alongside its fourth-quarter and full-year 2025 financial results.More about LENSARLENSAR, Inc. is a global medical technology company operating at the commercial stage that focuses on the design, development and marketing of advanced robotic laser systems used in cataract surgery and astigmatism management. Its flagship product, the ALLY Robotic Cataract Laser System, combines a high-speed dual-modality laser, artificial intelligence-driven imaging and Streamline software to support premium cataract procedures in operating rooms and office-based surgical suites, with the goal of improving surgical outcomes and efficiency.Building on its earlier LENSAR Laser System (LLS) platform, the company has expanded its installed base and procedure volumes since the commercial launch of ALLY in 2022. Through its emphasis on compact system design, ergonomic features and workflow optimization, LENSAR aims to strengthen its position in the growing premium cataract surgery market while deepening partnerships with surgeons and eye-care providers worldwide.LENSAR stock price

Original: LENSAR cancels Alcon merger agreement, prepares strategic update

LNSR, new 52 week high

LNSR under $5

Company is very silent. maybe merger coming with Sight. Could complement well and help negotiating with BP

I really really like this one!

Where do you see this going near term?

LNSR, Great start out of the gate.